Clinical TrialJul 14, 2026, 07:46 AM
Cardiol Therapeutics Phase II Pericarditis Data Published in JAHA
AI Summary
Cardiol Therapeutics announced the publication of its Phase II MAvERIC study results for CardiolRx™ in recurrent pericarditis in the Journal of the American Heart Association (JAHA). The study demonstrated rapid and sustained reductions in pain and inflammation, substantial reductions in pericarditis episodes, and a favorable safety profile. This publication strengthens the clinical rationale for the ongoing pivotal Phase III MAVERIC trial, which is nearing full patient enrollment.
Key Highlights
- Phase II MAvERIC study results for CardiolRx™ published in JAHA.
- Study showed rapid and sustained reductions in pericarditis pain and inflammation.
- Reported substantial reductions in pericarditis episodes per year.
- CardiolRx™ demonstrated a favorable safety and tolerability profile.
- Publication strengthens rationale for pivotal Phase III MAVERIC trial.
- Phase III MAVERIC trial is nearing full patient enrollment.
- CardiolRx™ has US FDA Orphan Drug Designation for pericarditis.
Price Impact
More from CRDL